Walleye Capital LLC Invests $1.92 Million in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Walleye Capital LLC acquired 86,203 shares of Kiniksa Pharmaceuticals valued at approximately $1.9 million, marking the establishment of a new position during the 1st quarter.
• Kiniksa Pharmaceuticals reported a quarterly EPS of $0.23, exceeding analysts' expectations, with revenue of $156.8 million compared to the estimated $145.21 million.
• Shares of Kiniksa Pharmaceuticals have seen a significant increase in target prices from analysts, with Wells Fargo raising their target from $30 to $42, indicating a positive outlook for the stock.

Walleye Capital LLC purchased a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 86,203 shares of the company's stock, valued at approximately $1,915,000. Walleye Capital LLC owned about 0.12% of Kiniksa Pharmaceuticals International at the end of the most recent reporting period.

Several other large investors have also modified their holdings of KNSA. Wells Fargo & Company MN lifted its stake in shares of Kiniksa Pharmaceuticals International by 54.7% during the fourth quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock valued at $417,000 after buying an additional 7,463 shares during the period. Barclays PLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 11.2% during the fourth quarter. Barclays PLC now owns 71,896 shares of the company's stock valued at $1,423,000 after buying an additional 7,267 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Kiniksa Pharmaceuticals International by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after buying an additional 29,300 shares during the period. MetLife Investment Management LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after buying an additional 1,374 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Kiniksa Pharmaceuticals International by 117.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after buying an additional 4,575 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

KNSA has been the topic of several recent analyst reports. Wedbush reissued an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Jefferies Financial Group increased their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Price Performance

KNSA traded up $0.78 during trading hours on Wednesday, reaching $35.06. 197,123 shares of the stock traded hands, compared to its average volume of 672,332. The firm's fifty day simple moving average is $30.51 and its two-hundred day simple moving average is $26.21. The company has a market cap of $2.60 billion, a price-to-earnings ratio of 880.92 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $35.22.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, insider John F. Paolini sold 29,325 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total value of $954,528.75. Following the sale, the insider directly owned 57,403 shares in the company, valued at $1,868,467.65. This trade represents a 33.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $33.77, for a total transaction of $547,074.00. Following the completion of the sale, the chief operating officer owned 40,215 shares in the company, valued at approximately $1,358,060.55. This represents a 28.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 532,312 shares of company stock worth $17,159,701 over the last 90 days. Corporate insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.